About > News

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Innovent Biologics, Inc. for Fully Human Monoclonal Antibody Drug Discovery

October 12th, 2017 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to Innovent Biologics, Inc., a leading biopharmaceutical company in China.  The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV. Harbour BioMed’s transgenic H2L2 platform enables biotechnology and pharmaceutical companies and academic research labs to accelerate new drug development by generating fully human antibodies. Under the licensing agreement, Innovent Biologics has rights to use the H2L2 platform for multiple projects over a multi-year licensing term. Harbour will receive an upfront payment, fees and milestones as …

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

January 7, 2018 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to BeiGene, Ltd. (NASDAQ: BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV. Harbour BioMed’s transgenic H2L2 platform enables biotechnology and pharmaceutical companies and academia to accelerate new drug development by generating fully human monoclonal antibodies. Under the licensing agreement, BeiGene has rights to use the H2L2 platform for multiple programs over a …

Harbour BioMed Enters Agreement to Develop Fully Human Antibody Fragments for Innovative CAR-T Therapy

January 8th, 2018 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has entered into an agreement with ImmunoChina Pharmaceuticals Co. Ltd. to develop fully human monoclonal antibody fragments for use in Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy. ImmunoChina is a biotech company focused on developing CAR-T therapy for the treatment of hematological malignancies and solid tumors. Under the agreement, ImmunoChina receives rights to use the fully human antibody fragments discovered by Harbour BioMed through its H2L2 transgenic mouse platform for the development of CAR-T based therapeutic solutions. Harbour will receive an upfront payment and milestones as well as royalties based on net sales. Specific …

Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused Biotechnology Company

Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused Biotechnology Company Transgenic Mouse Platform Technology Licensing to Continue, Expand to Include Collaborative Discovery/Development Partnerships December 19, 2016 09:00 AM Eastern Standard Time CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands–(BUSINESS WIRE)–Harbour BioMed, a recently established Shanghai-based company, today announced it has acquired Harbour Antibodies BV for cash and an equity interest in Harbour BioMed to create a new, global oncology-focused biotechnology company. The new company plans to leverage Harbour Antibodies’ patented transgenic mouse platforms to build an internal portfolio of next generation therapeutic antibodies for cancer, expand the range of partnerships and licenses around Harbour’s platforms, and capitalize on the …

Harbour News

Upcoming Events

Contact Us

Name: 
Email: 
Company: 
Message: 
Submit

Join Mailing List

Name: 
Email: 
Company: 
Submit